$STVN

Balachandran Madhavan sold $26K of STVN

Balachandran Madhavan sold 1,493 shares of Stevanato Group S.p.A. (STVN) at $17.09 on 2026-06-15.

Original reporting
SEC EDGAR · Balachandran Madhavan
Published Jun 26, 2026, 10:18 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
high confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the reported open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the disclosed size and lack of company-specific news make it unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the article provides no stated rationale and the dollar value is relatively small.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-26 (sale dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A. (STVN).

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Form 4 shows director Balachandran Madhavan sold 1,493 STVN shares on 2026-06-15 at $17.0900 for ~$25.5K, filed 2026-06-26.

Expected impact

Low likelihood of a sustained price move from this specific transaction size.

Evidence & confidence

The filing is a small, non-10b5-1 sale by a director with modest dollar value and no accompanying company-specific catalyst.

Market effects

No clear sector read-through; this is an isolated insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even small director sales can precede periods of underperformance, especially if not on a 10b5-1 plan—watch for follow-on selling or changes in guidance.

Key entities

  • Stevanato Group S.p.A.

    Subject of the Form 4 insider transaction disclosure (STVN).

  • Balachandran Madhavan

    Director who sold 1,493 shares on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.